Zobrazeno 1 - 10
of 163
pro vyhledávání: '"R, MacDougall"'
Autor:
Li-Pin Kao, Samy A.F. Morad, Traci S. Davis, Matthew R. MacDougall, Miki Kassai, Noha Abdelmageed, Todd E. Fox, Mark Kester, Thomas P. Loughran, Jr., Jose' L. Abad, Gemma Fabrias, Su-Fern Tan, David J. Feith, David F. Claxton, Sarah Spiegel, Kelsey H. Fisher-Wellman, Myles C. Cabot
Publikováno v:
Journal of Lipid Research, Vol 60, Iss 9, Pp 1590-1602 (2019)
The combination of daunorubicin (dnr) and cytarabine (Ara-C) is a cornerstone of treatment for acute myelogenous leukemia (AML); resistance to these drugs is a major cause of treatment failure. Ceramide, a sphingolipid (SL), plays a critical role in
Externí odkaz:
https://doaj.org/article/fd54fe2e27784a42b78f98d42562f8fa
Autor:
Samy A.F. Morad, Terence E. Ryan, P. Darrell Neufer, Tonya N. Zeczycki, Traci S. Davis, Matthew R. MacDougall, Todd E. Fox, Su-Fern Tan, David J. Feith, Thomas P. Loughran, Jr., Mark Kester, David F. Claxton, Brian M. Barth, Tye G. Deering, Myles C. Cabot
Publikováno v:
Journal of Lipid Research, Vol 57, Iss 7, Pp 1231-1242 (2016)
The objective of our study was to determine the mechanism of action of the short-chain ceramide analog, C6-ceramide, and the breast cancer drug, tamoxifen, which we show coactively depress viability and induce apoptosis in human acute myelogenous leu
Externí odkaz:
https://doaj.org/article/9225c311082346768466937465b8333a
Autor:
John T. Schiller, Elisabet de los Pinos, John R. MacDougall, Stephen Monks, Demetrios Vavvas, Hans E. Grossniklaus, Shin J. Kang, Roger McLaughlin, Sean Spring, Debaditya Bhattacharya, Sanghamitra Choudhary, Isabella Varsavsky, Rhonda C. Kines
Figure S1-video composites of real time AU-011 mediated killing of 92.1MEL cells; Figure S2-Killing and binding comparison of free IR700 dye to VLP conjugated IR700 (AU-011) on HeLa and 92.1MEL cells; Figure S3-Demonstration of both the AU-011 dose a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65937368bee13b587b2d2465c6a8cb69
https://doi.org/10.1158/1535-7163.22505503.v1
https://doi.org/10.1158/1535-7163.22505503.v1
Data from An Infrared Dye–Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma
Autor:
John T. Schiller, Elisabet de los Pinos, John R. MacDougall, Stephen Monks, Demetrios Vavvas, Hans E. Grossniklaus, Shin J. Kang, Roger McLaughlin, Sean Spring, Debaditya Bhattacharya, Sanghamitra Choudhary, Isabella Varsavsky, Rhonda C. Kines
The work outlined herein describes AU-011, a novel recombinant papillomavirus-like particle (VLP) drug conjugate and its initial evaluation as a potential treatment for primary uveal melanoma. The VLP is conjugated with a phthalocyanine photosensitiz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce7761e0f0a84671eedda72af241466e
https://doi.org/10.1158/1535-7163.c.6538090.v1
https://doi.org/10.1158/1535-7163.c.6538090.v1
Autor:
John R. MacDougall, Raymond Mak, John Bradley, Allison Simpson, Claire May, Lan Wei, Kendra Ouellette, Marty Olbrot, Jimmy Blair, Neil Dhawan, Wei Chen
Publikováno v:
Cancer Research. 83:2249-2249
TOS-358 is a first-in-class covalent inhibitor of PI3Kα and is currently in clinical development in a variety of solid malignancies. We have developed a fit-for-purpose pharmacodynamic assay to evaluate the target occupancy of TOS-358 in in vitro an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4a456949391642472ad772103280841
https://doi.org/10.1158/1538-7445.am2023-2249
https://doi.org/10.1158/1538-7445.am2023-2249
Publikováno v:
Cancer Research. 83:4946-4946
PI3Kα is frequently mutated in a variety of cancer types, and the PI3K-AKT signaling axis also plays a role in insulin signaling and glucose homeostasis. TOS-358 is a highly selective first-in-class covalent inhibitor of PI3Kα and is currently in c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae7d6f1095d79de00e863bdde35d289a
https://doi.org/10.1158/1538-7445.am2023-4946
https://doi.org/10.1158/1538-7445.am2023-4946
Autor:
John R. MacDougall, Mengqi Zhong, Hanne Merritt, Joselyn S. Del Cid, John Bradley, Raymond Mak, Neil Dhawan, Wei Chen
Publikováno v:
Cancer Research. 83:4945-4945
PI3Kα is the most mutated oncogene with a high mutation rate in breast, lung, colorectal, gastric, bladder, and other tumor types. However, current inhibitors have had little efficacy in the clinic due to their inability to achieve maximal PI3Kα ta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b8b74db29ecbdca38ad3648e072349a
https://doi.org/10.1158/1538-7445.am2023-4945
https://doi.org/10.1158/1538-7445.am2023-4945
Publikováno v:
Pathology. 55:S99
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c386a93bd5899d3ddf49063d8051585
https://doi.org/10.1016/j.pathol.2022.12.331
https://doi.org/10.1016/j.pathol.2022.12.331
Autor:
T. Badrick, K. Shirley, G. Quagliotto, M. May, E. Meumann, N. Leonard, P. Simos, R. MacDougall, E. Bursle
Publikováno v:
Pathology. 55:S99
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f5a759ffc4899d862b5a60d8cfef6ac
https://doi.org/10.1016/j.pathol.2022.12.330
https://doi.org/10.1016/j.pathol.2022.12.330
Autor:
Su Fern Tan, Samy A.F. Morad, Hong Gang Wang, Myles C. Cabot, Noha Abdelmageed, Thomas P. Loughran, David J. Feith, Li-Pin Kao, Mark Kester, Matthew R. MacDougall
Publikováno v:
Experimental Cell Research. 381:256-264
Acute myelogenous leukemia (AML) is a hematological malignancy marked by the accumulation of large numbers of immature myeloblasts in bone marrow. The overall prognosis in AML is poor; hence, there is a pressing need to improve treatment. Although th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f721e1e5ce1c639755cddfd3c23e847
https://doi.org/10.1016/j.yexcr.2019.05.021
https://doi.org/10.1016/j.yexcr.2019.05.021